Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 5
1999 5
2000 2
2001 9
2002 8
2003 15
2004 8
2005 13
2006 24
2007 28
2008 25
2009 25
2010 34
2011 47
2012 43
2013 42
2014 45
2015 39
2016 43
2017 37
2018 25
2019 25
2020 22
2021 17
2022 10
2023 22
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

546 results

Results by year

Filters applied: . Clear all
Page 1
Vitamin D in prostate cancer.
Trump DL, Aragon-Ching JB. Trump DL, et al. Asian J Androl. 2018 May-Jun;20(3):244-252. doi: 10.4103/aja.aja_14_18. Asian J Androl. 2018. PMID: 29667615 Free PMC article. Review.
The pleiotropic effects of paricalcitol: Beyond bone-mineral metabolism.
Egido J, Martínez-Castelao A, Bover J, Praga M, Torregrosa JV, Fernández-Giráldez E, Solozábal C. Egido J, et al. Nefrologia. 2016;36(1):10-8. doi: 10.1016/j.nefro.2015.11.003. Epub 2015 Dec 23. Nefrologia. 2016. PMID: 26705959 Free article. Review. English, Spanish.
The classic effect of paricalcitol is that of a mediator in mineral and bone homeostasis. However, recent studies have suggested that the benefits of treatment with paricalcitol go beyond PTH reduction and, for instance, it has a positive effect on cardiovascular di …
The classic effect of paricalcitol is that of a mediator in mineral and bone homeostasis. However, recent studies have suggested that …
Paricalcitol and Extended-Release Calcifediol for Treatment of Secondary Hyperparathyroidism in Non-Dialysis Chronic Kidney Disease: Results From a Network Meta-Analysis.
Franchi M, Gunnarsson J, Gonzales-Parra E, Ferreira A, Ström O, Corrao G. Franchi M, et al. J Clin Endocrinol Metab. 2023 Oct 18;108(11):e1424-e1432. doi: 10.1210/clinem/dgad289. J Clin Endocrinol Metab. 2023. PMID: 37235771 Free PMC article.
OBJECTIVE: The objective of this analysis was to compare the efficacy and adverse effects of extended-release calcifediol (ERC) and paricalcitol (PCT) by assessing their effect on the biomarkers PTH, calcium, and phosphate in patients with non-dialysis CKD (ND-CKD). ...
OBJECTIVE: The objective of this analysis was to compare the efficacy and adverse effects of extended-release calcifediol (ERC) and paric
Clinical Uses of 1,25-dihydroxy-19-nor-vitamin D(2) (Paricalcitol).
Bover J, Dasilva I, Furlano M, Lloret MJ, Diaz-Encarnacion MM, Ballarin J, Cozzolino M. Bover J, et al. Curr Vasc Pharmacol. 2014 Mar;12(2):313-23. doi: 10.2174/15701611113119990028. Curr Vasc Pharmacol. 2014. PMID: 23713879 Review.
As a result of its selectivity, paricalcitol provides a wider therapeutic window for PTH suppression, minimizing deleterious effects of high serum calcium and/or phosphate concentrations. ...Consequently, paricalcitol may enhance the standard of care in these …
As a result of its selectivity, paricalcitol provides a wider therapeutic window for PTH suppression, minimizing deleterious e …
Oral paricalcitol: expanding therapeutic options for pediatric chronic kidney disease patients.
Freundlich M, Abitbol CL. Freundlich M, et al. Pediatr Nephrol. 2017 Jul;32(7):1103-1108. doi: 10.1007/s00467-017-3675-7. Epub 2017 Apr 27. Pediatr Nephrol. 2017. PMID: 28451892
The complex pathophysiology of progressive chronic kidney disease (CKD) and the development of mineral and bone disorder, abbreviated as CKD-MBD, is of vital importance to a pediatric patient. Paricalcitol, the 19 nor-1,25(OH)(2)D(2) analogue was shown to be effective and …
The complex pathophysiology of progressive chronic kidney disease (CKD) and the development of mineral and bone disorder, abbreviated as CKD …
Spotlight on paricalcitol in secondary hyperparathyroidism.
Robinson DM, Scott LJ. Robinson DM, et al. Treat Endocrinol. 2005;4(3):185-6. doi: 10.2165/00024677-200504030-00007. Treat Endocrinol. 2005. PMID: 15898824 Review.
Paricalcitol (Zemplar) is a synthetic vitamin D2 analog that inhibits the secretion of parathyroid hormone (PTH) through binding to the vitamin D receptor. ...Thus, paricalcitol is a useful option for the management of secondary hyperparathyroidism in adults and chi
Paricalcitol (Zemplar) is a synthetic vitamin D2 analog that inhibits the secretion of parathyroid hormone (PTH) through binding to t
Tubular Elabela-APJ axis attenuates ischemia-reperfusion induced acute kidney injury and the following AKI-CKD transition by protecting renal microcirculation.
Xiong M, Chen H, Fan Y, Jin M, Yang D, Chen Y, Zhang Y, Petersen RB, Su H, Peng A, Wang C, Zheng L, Huang K. Xiong M, et al. Theranostics. 2023 Jun 4;13(10):3387-3401. doi: 10.7150/thno.84308. eCollection 2023. Theranostics. 2023. PMID: 37351176 Free PMC article.
Injured mice were treated with ELA32 peptide, Nomega-hydroxy-nor-L-arginine (nor-NOHA), prostaglandin E2 (PGE2), Paricalcitol, ML221 or respective vehicles, individually or in combination. ...Notably, combination application of an ARG2 inhibitor nor-NOHA, and Paricalcit
Injured mice were treated with ELA32 peptide, Nomega-hydroxy-nor-L-arginine (nor-NOHA), prostaglandin E2 (PGE2), Paricalcitol, ML221 …
Safety and tolerability of paricalcitol in patients with chronic kidney disease.
Dyer CA. Dyer CA. Expert Opin Drug Saf. 2013 Sep;12(5):717-28. doi: 10.1517/14740338.2013.791675. Epub 2013 Apr 29. Expert Opin Drug Saf. 2013. PMID: 23621417 Review.
AREAS COVERED: This review summarizes trials that established the safety and efficacy of paricalcitol for SHPT. Comparative experience with paricalcitol as against other VDRAs will be reviewed as will the experience with paricalcitol in non-dialysis CKD and c …
AREAS COVERED: This review summarizes trials that established the safety and efficacy of paricalcitol for SHPT. Comparative experienc …
Vitamin D and Glomerulonephritis.
Gembillo G, Siligato R, Amatruda M, Conti G, Santoro D. Gembillo G, et al. Medicina (Kaunas). 2021 Feb 22;57(2):186. doi: 10.3390/medicina57020186. Medicina (Kaunas). 2021. PMID: 33671780 Free PMC article. Review.
Maxalcalcitol is another promising alternative: it has about 1/600 affinity to vitamin D binding protein (DBP), compared to Calcitriol, overcoming the risk of hypercalcemia, hyperphosphatemia and calcifications, and it circulates principally in unbound form with easier availabili …
Maxalcalcitol is another promising alternative: it has about 1/600 affinity to vitamin D binding protein (DBP), compared to Calcitriol, over …
Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis.
Cheng J, Zhang W, Zhang X, Li X, Chen J. Cheng J, et al. Clin J Am Soc Nephrol. 2012 Mar;7(3):391-400. doi: 10.2215/CJN.03000311. Epub 2012 Jan 5. Clin J Am Soc Nephrol. 2012. PMID: 22223607 Review.
To systematically evaluate the efficacy and safety of paricalcitol for CKD, we conducted a meta-analysis of the published randomized controlled trials (RCTs). ...Compared with the control group, the RR for hypercalcemia associated with paricalcitol use was 2.25 (95% …
To systematically evaluate the efficacy and safety of paricalcitol for CKD, we conducted a meta-analysis of the published randomized …
546 results